• Lunai Bioworks published a CEO shareholder letter outlining a push to expand its AI-enabled biodefense platform.
• Highlighted a first revenue-generating, multi-year U.S. defense collaboration via BioSymetrics to deploy chemical threat assessment technology.
• Pointed to the Pathfinder Consortium with major academic partners to support biodefense work, with an eye on late-2026 opportunities.
• Detailed a Delaware federal lawsuit alleging naked short selling, citing 29,600,000 fails-to-deliver, 81.6% of shares outstanding.
• Noted peak March 17, 2026 trading volume of 554,000,000 shares; court granted expedited discovery on a prima facie showing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-000871), on June 17, 2026, and is solely responsible for the information contained therein.